The legal action targets Regeneron and its senior leadership, questioning the transparency of their business practices. The scrutiny intensified on April 29, 2026, when the company revealed modifications to its Phase III Fianlimab-Libtayo study, a move that prompted a 6.21% decline in share value. The situation deteriorated further on May 15, 2026, when Regeneron confirmed the trial failed to reach statistical significance for its primary progression-free survival endpoint. That disclosure triggered a sharper market reaction, with the stock price falling an additional 9.82% by the close of the following trading day.

Pomerantz LLP, the firm spearheading the action, invites affected shareholders to contact Danielle Peyton to provide documentation regarding their holdings. The firm argues that these developments constitute grounds for recovery of damages for investors who acquired securities during the specified class period. While the legal proceedings move forward, the firm notes that previous litigation outcomes do not guarantee future success in this case.